Publications by authors named "Carmelo Ioppolo"

In patients with COVID-19, high-flow nasal cannula (HFNC) and continuous positive airway pressure (CPAP) are widely applied as initial treatments for moderate-to-severe acute hypoxemic respiratory failure. The aim of the study was to assess which respiratory supports improve 28-day mortality and to identify a predictive index of treatment response. This is a single-center retrospective observational study including 159 consecutive adult patients with COVID-19 and moderate-to-severe hypoxemic acute respiratory failure.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the prognostic value of N-terminal pro-Brain Natriuretic Peptide (NT-pro-BNP) in 107 COVID-19 patients at the Covid Hospital of Messina University, focusing on in-hospital mortality rates.
  • - Results indicated that patients who died had higher NT-pro-BNP levels, older age, lower Glasgow Coma Scale scores, and other concerning lab values, with an overall in-hospital mortality rate of 25.2%.
  • - The findings suggest that NT-pro-BNP, along with PT and PaO/FiO ratio, serve as independent predictors of mortality in COVID-19 pneumonia patients, highlighting the need for more research to validate these results.
View Article and Find Full Text PDF

: COVID-19 is associated with an aberrant inflammatory response that may trigger new-onset cardiac arrhythmias. The aim of this study was to assess the mortality risk in hospitalized COVID-19 patients according to IL-6 serum levels and new-onset atrial fibrillation (AF) according to PaO/FiO stratification. : 175 COVID-19 patients (25 new-onset AF, 22 other types of AF and 128 no-AF) were included in this single-center, retrospective study; clinical and demographic data, vital signs, electrocardiograms and laboratory results were collected and analyzed.

View Article and Find Full Text PDF

Autologous hematopoietic stem cells transplantation (AHSCT) has been employed as treatment for severe systemic sclerosis (SSc) with high risk of organ failure. In the last 25 years overall survival and treatment-related mortality have improved, in accordance with a better patient selection and mobilization and conditioning protocols. This review analyzes the evidence from the last 5 years for AHSCT-treated SSc patients, considering in particular the outcomes related to interstitial lung disease.

View Article and Find Full Text PDF

Objective: Systemic sclerosis (SSc) mortality is extremely variable in its internal organ involvement. Pulmonary fibrosis occurs in up to 30% of the cases. Animal models provide evidence that IL-33 is able to induce both cutaneous and pulmonary fibrosis via increased IL-13 and in SSc patients the levels of IL-33 correlate with skin fibrosis.

View Article and Find Full Text PDF
Article Synopsis
  • Systemic sclerosis (SSc) is a rare disease that can affect different parts of the body and can be very serious, especially affecting the lungs and heart.
  • New research has found new treatments for SSc-related lung disease, and recent clinical trials have studied how well these treatments work.
  • The most common medicines for treating this lung issue in SSc are cyclophosphamide and mycophenolate mofetil, while other drugs like nintedanib and tocilizumab can help slow down problems with breathing.
View Article and Find Full Text PDF

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) represents a public health problem worldwide. COVID-19 triggers a maladaptive cytokine release commonly referred to as cytokine storm syndrome with increased production of proinflammatory cytokines, which also appears to contribute to chronic neuroinflammation and neurodegenerative disorders' appearance, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease. In this context, SARS-CoV-2 might enter the central nervous system through binding with the angiotensin converting enzyme 2 receptors which are highly expressed in glial cells and neurons.

View Article and Find Full Text PDF

Coronavirus disease 2019 (COVID-19) is a disease with a high rate of progression to critical illness. However, the stratification of patients at risk of mortality is not well defined. In this study, we aimed to define a mortality risk index to allocate patients to the appropriate intensity of care.

View Article and Find Full Text PDF